Hantavirus vaccine gap exposed as cruise-ship outbreak unfolds

The cruise-ship hantavirus outbreak (Andes virus) starkly highlights that there is no approved vaccine or targeted treatment, with decades of vaccine research led by Jay Hooper facing barriers like multi-dose regimens, rarity of human cases complicating trials, and chronic funding gaps. Researchers are exploring neutralizing antibodies as a surrogate for protection and pursuing creative licensing paths, but a traditional phase III trial is difficult due to the virus’s scattered cases. Climate-driven shifts in rodent populations may further elevate future outbreak risks.